Lexicon Pharmaceuticals
CompanyUnited StatesFounded 1995
Lexicon Pharmaceuticals develops one asset, approved (sotagliflozin in cardiovascular death). Mostly small molecule acting on lipid and ceramide metabolism, SLC5A2 and SLC5A1; based in the United States, founded in 1995.
- 1
- Asset
- Furthest
- Approved
- 27
- Trials
- 0
- Signals
Pipeline
1Dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT1/SGLT2)
Approved, Small molecule, Lipid and ceramide metabolism, SLC5A2, cardiovascular death, chronic kidney disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials31
- Similar companies6
Updated 9 Oct 2026 · 52 sources